ATE368656T1 - Piperidinderivate zur verwendung bei der behandlung von durch chemokins vermittelten leiden - Google Patents

Piperidinderivate zur verwendung bei der behandlung von durch chemokins vermittelten leiden

Info

Publication number
ATE368656T1
ATE368656T1 AT03798620T AT03798620T ATE368656T1 AT E368656 T1 ATE368656 T1 AT E368656T1 AT 03798620 T AT03798620 T AT 03798620T AT 03798620 T AT03798620 T AT 03798620T AT E368656 T1 ATE368656 T1 AT E368656T1
Authority
AT
Austria
Prior art keywords
chemokine
treatment
piperidine derivatives
mediated conditions
formula
Prior art date
Application number
AT03798620T
Other languages
English (en)
Inventor
Christopher Luckhurst
Matthew Perry
Brian Springthorpe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE368656T1 publication Critical patent/ATE368656T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
AT03798620T 2002-09-24 2003-09-12 Piperidinderivate zur verwendung bei der behandlung von durch chemokins vermittelten leiden ATE368656T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202838A SE0202838D0 (sv) 2002-09-24 2002-09-24 Chemical compounds

Publications (1)

Publication Number Publication Date
ATE368656T1 true ATE368656T1 (de) 2007-08-15

Family

ID=20289093

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03798620T ATE368656T1 (de) 2002-09-24 2003-09-12 Piperidinderivate zur verwendung bei der behandlung von durch chemokins vermittelten leiden

Country Status (20)

Country Link
US (1) US20060040984A1 (de)
EP (2) EP1546130B1 (de)
JP (1) JP2006503066A (de)
KR (1) KR20050052511A (de)
CN (1) CN1684952A (de)
AT (1) ATE368656T1 (de)
AU (1) AU2003259004B2 (de)
BR (1) BR0314688A (de)
CA (1) CA2497280A1 (de)
DE (1) DE60315323T2 (de)
ES (1) ES2289354T3 (de)
IS (1) IS7813A (de)
MX (1) MXPA05003007A (de)
NO (1) NO20051965L (de)
NZ (1) NZ538527A (de)
PL (1) PL376119A1 (de)
RU (1) RU2005105053A (de)
SE (1) SE0202838D0 (de)
WO (1) WO2004029041A1 (de)
ZA (1) ZA200502341B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
EP1604982A1 (de) 2001-07-02 2005-12-14 AstraZeneca AB Zwischenverbindungen für die herstellung von piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
US6949590B2 (en) * 2002-01-10 2005-09-27 University Of Washington Hydrogels formed by non-covalent linkages
SE0200844D0 (sv) * 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) * 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0300957D0 (sv) * 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
SE0301368D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
GB0417804D0 (en) * 2004-08-10 2004-09-15 Novartis Ag Organic compounds
KR100896546B1 (ko) 2004-08-10 2009-05-07 노파르티스 아게 Ｃｃｒ３ 억제 활성을 갖는 피페라진 유도체
WO2006126948A1 (en) * 2005-05-27 2006-11-30 Astrazeneca Ab Piperidines for the treatment of chemokine mediated diseases
TW200722419A (en) * 2005-05-27 2007-06-16 Astrazeneca Ab Chemical compounds
BRPI0613563A2 (pt) 2005-07-21 2012-01-17 Astrazeneca Ab novos derivados de piperidina
US7781437B2 (en) 2005-10-11 2010-08-24 Schering Corporation Substituted heterocyclic compounds with CXCR3 antagonist activity
TWI433838B (zh) * 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) * 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
BR112013011737A2 (pt) 2010-11-15 2016-08-09 Univ Leuven Kath composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv
KR101939710B1 (ko) 2011-12-21 2019-01-17 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
UY34993A (es) 2012-08-28 2014-02-28 Janssen R & D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
WO2014131847A1 (en) 2013-02-28 2014-09-04 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
JP6419155B2 (ja) 2013-04-03 2018-11-07 ヤンセン・サイエンシズ・アイルランド・ユーシー Ｎ−フェニル−カルボキサミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用
HRP20181863T1 (hr) 2013-05-17 2018-12-28 Janssen Sciences Ireland Uc Derivati sulfamoiltiofenamida i njihova uporaba kao lijekova za liječenje hepatitisa b
JO3583B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
NO3024819T3 (de) 2013-07-25 2018-07-21
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
WO2015120178A1 (en) 2014-02-05 2015-08-13 Novira Therapeutics, Inc. Combination therapy for treatment of hbv infections
DK3102572T3 (en) 2014-02-06 2019-02-04 Janssen Sciences Ireland Uc SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
HK1247147A1 (zh) 2015-03-19 2018-09-21 诺维拉治疗公司 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108430971A (zh) 2015-09-29 2018-08-21 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
KR20180129943A (ko) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 캡시드 조립 억제제를 포함하는 배합물 및 방법
JP2021515769A (ja) 2018-03-14 2021-06-24 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カプシド集合調節剤の投薬レジメン
US11096931B2 (en) 2019-02-22 2021-08-24 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4505915A (en) * 1979-05-29 1985-03-19 Merck & Co., Inc. 6-N-Heterocyclyl penicillins
US4588722A (en) * 1984-01-09 1986-05-13 Janssen Pharmaceutica N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
US4695575A (en) * 1984-11-13 1987-09-22 Janssen Pharmaceutica, N.V. 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5952349A (en) * 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
NZ333513A (en) * 1996-07-10 2000-04-28 Schering Corp 1,4-di-substituted piperidines and medicaments useful as muscarinic antagonists
US5977138A (en) * 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
CZ43399A3 (cs) * 1996-08-15 1999-07-14 Schering Corporation Etheroví muskarinní antagonisté
TWI245763B (en) * 1998-04-02 2005-12-21 Janssen Pharmaceutica Nv Biocidal benzylbiphenyl derivatives
US6294555B1 (en) * 1998-04-28 2001-09-25 Dainippon Pharmaceutical Co., Ltd. 1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivative, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
US6066636A (en) * 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
CN1146559C (zh) * 1998-06-30 2004-04-21 先灵公司 毒蕈碱性拮抗剂
CA2347912A1 (en) * 1998-12-18 2000-06-22 Soo S. Ko Heterocyclic piperidines as modulators of chemokine receptor activity
US6387930B1 (en) * 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
US6294554B1 (en) * 1999-09-22 2001-09-25 Schering Corporation Muscarinic antagonists
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0108876D0 (en) * 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
EP1604982A1 (de) * 2001-07-02 2005-12-14 AstraZeneca AB Zwischenverbindungen für die herstellung von piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
GB0117899D0 (en) * 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
GB0120461D0 (en) * 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
GB0122503D0 (en) * 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) * 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) * 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0300850D0 (sv) * 2003-03-25 2003-03-25 Astrazeneca Ab Chemical compounds
SE0300957D0 (sv) * 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
SE0301368D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
DE60315323T2 (de) 2008-04-17
EP1546130A1 (de) 2005-06-29
RU2005105053A (ru) 2005-12-10
KR20050052511A (ko) 2005-06-02
ZA200502341B (en) 2005-09-19
EP1546130B1 (de) 2007-08-01
ES2289354T3 (es) 2008-02-01
SE0202838D0 (sv) 2002-09-24
DE60315323D1 (de) 2007-09-13
AU2003259004B2 (en) 2007-02-08
IS7813A (is) 2005-04-20
JP2006503066A (ja) 2006-01-26
CN1684952A (zh) 2005-10-19
NO20051965L (no) 2005-06-23
AU2003259004A1 (en) 2004-04-19
MXPA05003007A (es) 2005-06-22
NZ538527A (en) 2006-10-27
EP1816123A1 (de) 2007-08-08
BR0314688A (pt) 2005-08-02
PL376119A1 (en) 2005-12-12
US20060040984A1 (en) 2006-02-23
CA2497280A1 (en) 2004-04-08
NO20051965D0 (no) 2005-04-22
WO2004029041A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
DE60315323D1 (de) Piperidinderivate zur verwendung bei der behandlung von durch chemokins vermittelten leiden
CY1106969T1 (el) Αναστολεις dpp-iv
DE50306845D1 (de) Disubstituierte thiazolylcarboxanilide und ihre verwendung als mikrobizide
ATE396190T1 (de) Substituierte heteroarylalkansäure und ihre verwendung als inhibitoren der aldose reductase
NO20062339L (no) Hepatitt C virus-inhibitoerer
ATE406353T1 (de) Piperidin-derivaten und deren verwendung bei der behandlung von durch chemokinen oder h1 vermittelten krankheiten
DE69915004D1 (de) 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
DE60336867D1 (de) Verfahren zur Herstellung von 3-Halo-4,5-Dihydro-1H-Pyrazolen
NO20062267L (no) Hepatitt C virus inhibitorer
DE50312946D1 (de) Difluormethyl thiazolyl carboxanilide
ZA200309887B (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
DE60330407D1 (de) Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
NO20044807L (no) Heratitt C virus inhibitorer
ATE250590T1 (de) Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems
ATE275554T1 (de) Serinprotease-inhibitoren
DE60012751D1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
ATE413388T1 (de) Muskarin antagonisten
MXPA05012268A (es) N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa.
DK1277736T3 (da) Hidtil ukendte bicykliske forbindelser
BRPI0409376A (pt) derivados de indeno como agentes farmacêuticos
ATE360012T1 (de) Heterozyklische carboxamide und ihre verwendung als fungizide
SE0200843D0 (sv) Chemical compounds
NO20060314L (no) Nicotinamid-derivater anvendbare som PDE4-inhibitorer
SE0300957D0 (sv) Chemical compounds
BR0312586A (pt) Derivados de pirolidina como antagonistas e oxitocina

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties